Sanofi’s new chief executive Belén Garijo has spoken publicly for the first time about her plans to turn around the French pharmaceutical giant’s recent run of clinical disappointments.
Garijo outlined a strategic shift that includes dropping itepekimab, an IL-33 candidate developed in partnership with Regeneron Pharmaceuticals (REGN), marking a significant change in direction for the company.
The decision to cut itepekimab signals that Garijo is willing to make bold portfolio choices as she asserts her leadership over one of Europe’s largest drugmakers.
Sanofi has faced a difficult period of late, with a series of clinical setbacks undermining investor confidence and raising questions about the strength of its pipeline.
The Regeneron partnership, while historically productive for both companies, will now see one of its key collaborative programmes discontinued under Garijo’s new strategic framework.
Itepekimab had been developed as a potential treatment targeting the IL-33 pathway, an area of significant scientific interest in respiratory and inflammatory diseases.
Garijo’s willingness to exit the programme suggests she is prioritising focus and capital allocation over maintaining legacy partnerships for their own sake.
The move is likely to be closely watched by analysts and investors who have been waiting for clear signals about where Sanofi intends to concentrate its research and development resources.
Sanofi trades on the Paris stock exchange as well as on the Nasdaq under the ticker SNY, giving it a broad international investor base that will be scrutinising these strategic announcements carefully.
Garijo’s first major public strategic statement sets an early tone for her tenure, suggesting a leadership style focused on hard decisions and pipeline discipline rather than incremental change.